Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Opticell Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. The company's current patent activity is focused on this single matter, which suggests a highly targeted approach to its intellectual property in this field. By operating within 1 distinct art unit, the applicant can focus on the specific procedural requirements and examination trends of that particular office division.
BURKHART, MICHAEL D is the busiest examiner, responsible for 1 pending office action. Since there is only 1 pending office action in the portfolio, this examiner is the sole reviewer for the company's active filings. This concentration within one art unit provides a clear and singular path for prosecution. Practitioners should tailor their arguments to the specific feedback provided by BURKHART, MICHAEL D to efficiently move the 1 pending office action toward allowance. This lack of dispersion across multiple examiners or units reduces the administrative complexity of the company's patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565253 | CELL CULTURE SUPPLEMENT FOR PRODUCING STEM CELLS, AND METHOD FOR PRODUCING STEM CELLS | BURKHART, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565253 | CELL CULTURE SUPPLEMENT FOR PRODUCING STEM CELLS, AND METHOD FOR PRODUCING STEM CELLS | BURKHART, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565253 | CELL CULTURE SUPPLEMENT FOR PRODUCING STEM CELLS, AND METHOD FOR PRODUCING STEM CELLS | BURKHART, MICHAEL D | 1638 | §102§112 | Final Rejection | — | Pending | Nov 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOpticell Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Burkhart has the most, with 1 of Opticell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
